We previously reported that South Korean biopharmaceutical company Alteogen submitted its Marketing Authorization Application to the European Medicines Agency (“EMA”) for ALT-L9, what has since been named EYLUXVI. EYLUXVI is a proposed biosimilar to Regeneron’s EYLEA (aflibercept). Alteogen had previously announced clinical results demonstrating similarity between EYLUXVI and EYLEA. On…
